Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of a Second Dose of RSVpreF Vaccine in Older Adults
NCT07885956Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Feb 2029
01
Overview
Phase 3, randomised, open-label trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions at 7 days, Percentage of participants reporting systemic events at 7 days and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07885956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885956.